Chen Jinhua, Chen Ying, Pu Jiali
Eur Neurol. 2018;79(5-6):256-265. doi: 10.1159/000488938. Epub 2018 Apr 27.
Parkinson's disease (PD) is characterized by the selective loss of dopaminergic neurons in the midbrain. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. There is increasing evidence that leucine-rich repeat kinase 2 (LRRK2) plays a significant role in PD pathophysiology.
Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, we discuss the role of LRRK2 in PD and recent progress in the use of LRRK2 inhibitors as therapeutic agents. Key Messages: LRRK2 plays a significant role in the pathophysiology of PD, and pharmacological inhibition of LRRK2 has become one of the most promising potential therapies for PD. Further research is warranted to determine the functions of LRRK2 and expand the applications of LRRK2 inhibitors in PD treatment.
帕金森病（PD）的特征是中脑多巴胺能神经元的选择性丧失。PD的发病机制尚未完全明确，但可能是由遗传和环境因素共同导致的。有几个基因与家族性PD的发病和进展相关。越来越多的证据表明，富含亮氨酸重复激酶2（LRRK2）在PD病理生理学中起重要作用。
已经开展了许多研究来阐明LRRK2的功能，并确定用于PD治疗的有效LRRK2抑制剂。在本综述中，我们讨论了LRRK2在PD中的作用以及将LRRK2抑制剂用作治疗药物的最新进展。关键信息：LRRK2在PD病理生理学中起重要作用，对LRRK2的药理学抑制已成为PD最有前景的潜在治疗方法之一。有必要进一步开展研究以确定LRRK2的功能，并扩大LRRK2抑制剂在PD治疗中的应用。
